Goldman Sachs analyst Matthew Sykes maintained a Buy rating on Qiagen yesterday. The company’s shares closed last Tuesday at $47.00.
According to TipRanks.com, Sykes is a 2-star analyst with an average return of 4.0% and a 47.1% success rate. Sykes covers the Healthcare sector, focusing on stocks such as Twist Bioscience, Myriad Genetics, and Guardant Health.
Qiagen has an analyst consensus of Moderate Buy, with a price target consensus of $62.50.
Credit Suisse analyst Dominic Lunn maintained a Buy rating on Sanofi yesterday and set a price target of EUR96.00. The company’s shares closed last Monday at $106.24.
According to TipRanks.com, Lunn is ranked #4599 out of 7545 analysts.
Currently, the analyst consensus on Sanofi is a Moderate Buy with an average price target of $120.76, a 13.7% upside from current levels. In a report issued on May 28, Kepler Capital also maintained a Buy rating on the stock with a EUR105.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.